MedTrace Logo

Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)

NCT00647023 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2008-03-31

No results posted yet for this study

Summary

The incretin hormones are secreted from the gastrointestinal tract in response to nutrient ingestion, and are responsible for 70 % of insulin secretion in response to glucose. The incretin response is attenuated in subjects with type 2 diabetes and other conditions associated with insulin resistance. Polycystic ovary syndrome (PCOS) is characterised by irregular periods and increased androgen levels. It is the most common endocrine disorder amongst young women at fertile age, and the most common cause of female infertility. Insulin resistance plays an important role in the development of the disease, and women with PCOS are at increased risk of developing tyoe 2 diabetes. the incretin hormones have not previously been investigated in women with PCOS, and the purpose of the present study was to investigate the secretion of the two most important incretin hormones Glucose-like peptide-1 (GLP-1) and Glucose dependent insulinotropic peptide (GIP) during a three hour oral glucose tolerance test.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

metformin

1000 mg metformin x 2 daily during 8 months

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Hvidovre University Hospital

    lead OTHER

Study Design

Purpose
BASIC_SCIENCE

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2006-05-31
Completion
2006-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647023 on ClinicalTrials.gov